Dialysis-Related Beta-2m Amyloidosis Differential Diagnoses

1. Scarpioni R, Ricardi M, Albertazzi V, De Amicis S, Rastelli F, Zerbini L. Dialysis-related amyloidosis: challenges and solutions. Int J Nephrol Renovasc Dis. 2016 Dec 7. 9:319-328. [QxMD MEDLINE Link]. [Full Text].

2. Drueke TB. Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant. 2000. 15 Suppl 1:17-24. [QxMD MEDLINE Link].

3. Tan SY, Baillod R, Brown E, Farrington K, Soper C, Percy M, et al. Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1999 Jun. 14(6):1467-71. [QxMD MEDLINE Link].

4. Bely M, Kapp P, Szabo TS, Lakatos T, Apáthy A. Electron microscopic characteristics of beta2-microglobulin amyloid deposits in long-term haemodialysis. Ultrastruct Pathol. 2005 Nov-Dec. 29(6):483-91. [QxMD MEDLINE Link].

5. Uji Y, Motomiya Y, Ando Y. A Circulating beta(2)-Microglobulin Intermediate in Hemodialysis Patients. Nephron Clin Pract. 2009 Feb 5. 111(3):c173-c181. [QxMD MEDLINE Link].

6. Thornalley PJ. Glycation free adduct accumulation in renal disease: the new AGE. Pediatr Nephrol. 2005 Nov. 20(11):1515-22. [QxMD MEDLINE Link].

7. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996 Sep 1. 98(5):1088-94. [QxMD MEDLINE Link].

8. Jadoul M, Garbar C, Vanholder R, Sennesael J, Michel C, Robert A, et al. Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int. 1998 Sep. 54(3):956-9. [QxMD MEDLINE Link].

9. Fry AC, Singh DK, Chandna SM, Farrington K. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif. 2007. 25(3):295-302. [QxMD MEDLINE Link].

10. Danesh F, Ho LT. Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial. 2001 Mar-Apr;14(2):80-5. [QxMD MEDLINE Link].

11. Saito A, Gejyo F. Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients. Ther Apher Dial. 2006 Aug. 10(4):316-20. [QxMD MEDLINE Link].

12. Kelly A, Apostle K, Sanders D, Bailey H. Musculoskeletal pain in dialysis-related amyloidosis. Can J Surg. 2007 Aug. 50(4):305-6. [QxMD MEDLINE Link].

13. Yamamoto S, Kazama JJ, Maruyama H, Nishi S, Narita I, Gejyo F. Patients undergoing dialysis therapy for 30 years or more survive with serious osteoarticular disorders. Clin Nephrol. 2008 Dec. 70(6):496-502. [QxMD MEDLINE Link].

14. Matsumoto K, Kikuchi J, Kaneko Y, Yasuoka H, Suzuki K, Tokuyama H, et al. Persistent fever and destructive arthritis caused by dialysis-related amyloidosis: A case report. Medicine (Baltimore). 2018 Jan. 97 (1):e9359. [QxMD MEDLINE Link]. [Full Text].

15. Matsuo K, Nakamoto M, Yasunaga C, Goya T, Sugimachi K. Dialysis-related amyloidosis of the tongue in long-term hemodialysis patients. Kidney Int. 1997 Sep. 52(3):832-8. [QxMD MEDLINE Link].

16. Portales-Castillo I, Yee J, Tanaka H, Fenves AZ. Beta-2 Microglobulin Amyloidosis: Past, Present, and Future. Kidney360. 2020 Dec 31. 1 (12):1447-1455. [QxMD MEDLINE Link]. [Full Text].

17. Hoshino J, Kawada M, Imafuku A, Mise K, Sumida K, Hiramatsu R, et al. A clinical staging score to measure the severity of dialysis-related amyloidosis. Clin Exp Nephrol. 2016 Jun 23. [QxMD MEDLINE Link].

18. Kiss E, Keusch G, Zanetti M, Jung T, Schwarz A, Schocke M, et al. Dialysis-related amyloidosis revisited. AJR Am J Roentgenol. 2005 Dec. 185(6):1460-7. [QxMD MEDLINE Link].

19. Santagati G, Cataldo E, Columbano V, Chatrenet A, Penna D, Pelosi E, et al. Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis. J Clin Med. 2019 Sep 19. 8 (9):[QxMD MEDLINE Link]. [Full Text].

20. Piccoli GB, Hachemi M, Molfino I, Coindre JP, Boursot C. Doxycycline treatment in dialysis related amyloidosis: discrepancy between antalgic effect and inflammation, studied with FDG-positron emission tomography: a case report. BMC Nephrol. 2017 Sep 6. 18 (1):285. [QxMD MEDLINE Link]. [Full Text].

21. FDA authorizes use of first device to treat patients with dialysis-related amyloidosis. U.S. Food & Drug Administration. Available at http://www.medscape.com/viewarticle/841337. March 11, 2015; Accessed: June 27, 2022.

22. Tsuruya K, Arima H, Iseki K, Hirakata H, Kyushu Dialysis-Related Amyloidosis Study Group. Association of dialysis-related amyloidosis with lower quality of life in patients undergoing hemodialysis for more than 10 years: The Kyushu Dialysis-Related Amyloidosis Study. PLoS One. 2021. 16 (8):e0256421. [QxMD MEDLINE Link]. [Full Text].

23. Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P, D'Haenens P. On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant. 2000. 15 Suppl 1:49-54. [QxMD MEDLINE Link].

24. Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif. 2005. 23(4):311-6. [QxMD MEDLINE Link].

25. Davankov V, Pavlova L, Tsyurupa M, Brady J, Balsamo M, Yousha E. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J Chromatogr B Biomed Sci Appl. 2000 Feb 28. 739(1):73-80. [QxMD MEDLINE Link].

26. [Guideline] National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003 Oct. 42 (4 Suppl 3):S1-201. [QxMD MEDLINE Link]. [Full Text].

27. Kutsuki H. beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis. Biochim Biophys Acta. 2005 Nov 10. 1753(1):141-5. [QxMD MEDLINE Link].

28. Ozawa D, Yagi H, Ban T, Kameda A, Kawakami T, Naiki H, et al. Destruction of amyloid fibrils of a beta2-microglobulin fragment by laser beam irradiation. J Biol Chem. 2009 Jan 9. 284(2):1009-17. [QxMD MEDLINE Link].

Anita Basu, MD, FACP Assistant Professor of Medicine, University of Mississippi School of Medicine; Staff Nephrologist, GV (Sonny) Montgomery Veterans Affairs Medical Center

Anita Basu, MD, FACP is a member of the following medical societies: American College of Physicians, National Kidney Foundation

Disclosure: Nothing to disclose.

Reynaldo Matute, MD Clinical Assistant Professor, Department of Internal Medicine, Division of Nephrology, New York Medical College

Reynaldo Matute, MD is a member of the following medical societies: American Society of Nephrology, National Kidney Foundation

Disclosure: Nothing to disclose.

Carol A Bogdan, MD Consultant in Hematology-Oncology, Myrtle Beach, SC

Disclosure: Nothing to disclose.

Vecihi Batuman, MD, FASN Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

George R Aronoff, MD Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Donald A Feinfeld, MD, FACP, FASN Consulting Staff, Division of Nephrology & Hypertension, Beth Israel Medical Center

Donald A Feinfeld, MD, FACP, FASN is a member of the following medical societies: American Academy of Clinical Toxicology, American Society of Hypertension, American Society of Nephrology, and National Kidney Foundation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

• Print this section
• Print the entire contents of
• Print the entire contents of article